These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 12576893)

  • 1. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
    Saw RP; Morgan M; Koorey D; Painter D; Findlay M; Stevens G; Clarke S; Chapuis P; Solomon MJ
    Dis Colon Rectum; 2003 Feb; 46(2):192-202. PubMed ID: 12576893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer.
    Saw RP; Koorey D; Painter D; Gallagher PJ; Solomon MJ
    Br J Surg; 2002 Nov; 89(11):1409-15. PubMed ID: 12390383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
    Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
    Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.
    Conradi LC; Bleckmann A; Schirmer M; Sprenger T; Jo P; Homayounfar K; Wolff HA; Rothe H; Middel P; Becker H; Ghadimi MB; Beissbarth T; Liersch T
    Ann Surg Oncol; 2011 Sep; 18(9):2442-52. PubMed ID: 21347782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors.
    Spindler KL; Nielsen JN; Lindebjerg J; Jakobsen A
    Dis Colon Rectum; 2007 Sep; 50(9):1363-9. PubMed ID: 17661145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Becker H; Baretton GB; Aust DE
    World J Gastroenterol; 2008 Feb; 14(7):1060-6. PubMed ID: 18286688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    Hur H; Kang J; Kim NK; Min BS; Lee KY; Shin SJ; Keum KC; Choi J; Kim H; Choi SH; Lee MY
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):669-76. PubMed ID: 20932673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    Jakob C; Aust DE; Meyer W; Baretton GB; Schwabe W; Häusler P; Becker H; Liersch T
    J Pathol; 2004 Dec; 204(5):562-8. PubMed ID: 15538739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Baretton GB; Häusler P; Schwabe W; Becker H; Aust DE
    Am J Surg Pathol; 2005 Oct; 29(10):1304-9. PubMed ID: 16160472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer.
    Broll R; Busch P; Duchrow M; Oevermann E; Schwandner O; Farke S; Bruch HP; Windhövel U
    Int J Colorectal Dis; 2005 Mar; 20(2):94-102. PubMed ID: 15309465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.
    Tan BR; Thomas F; Myerson RJ; Zehnbauer B; Trinkaus K; Malyapa RS; Mutch MG; Abbey EE; Alyasiry A; Fleshman JW; McLeod HL
    J Clin Oncol; 2011 Mar; 29(7):875-83. PubMed ID: 21205745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma.
    Luna-Perez P; Arriola EL; Cuadra Y; Alvarado I; Quintero A
    Ann Surg Oncol; 1998; 5(3):203-8. PubMed ID: 9607618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?
    Elsaleh H; Robbins P; Joseph D; Powell B; Grieu F; Menso L; Iacopetta B
    Radiother Oncol; 2000 Aug; 56(2):239-44. PubMed ID: 10927144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection.
    Rödel F; Hoffmann J; Grabenbauer GG; Papadopoulos T; Weiss C; Günther K; Schick C; Sauer R; Rödel C
    Strahlenther Onkol; 2002 Aug; 178(8):426-35. PubMed ID: 12240548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor location.
    Gervaz P; Bouzourene H; Cerottini JP; Chaubert P; Benhattar J; Secic M; Wexner S; Givel JC; Belin B
    Dis Colon Rectum; 2001 Mar; 44(3):364-72; discussion 372-3. PubMed ID: 11289282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
    Terzi C; Canda AE; Sagol O; Atila K; Sonmez D; Fuzun M; Gorken IB; Oztop I; Obuz F
    Int J Colorectal Dis; 2008 Jan; 23(1):37-45. PubMed ID: 17805549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Baretton GB; Schwabe W; Häusler P; Kulle B; Becker H; Aust DE
    Am J Surg Pathol; 2006 Sep; 30(9):1169-74. PubMed ID: 16931962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.